How Can Pharma Companies Join the Digital Therapeutics Revolution?

Guidehouse’s Maya Desai and Andrew Fraser address the various steps digital therapeutics companies should be considering as they build their launch playbooks beyond the traditional commercial activities.

By Maya Desai and Andrew Fraser, Guidehouse

More and more companies are joining forces with software developers to create innovative products. But many are learning the hard way that making next-generation digital therapeutics isn’t as easy as signing a partnership agreement. Guidehouse’s Maya Desai and Andrew Fraser address the various steps digital therapeutics companies should be considering as they build their launch playbooks beyond the traditional commercial activities.

Read the full article in PharmExec